These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38067362)

  • 1. Schlafen Family Intra-Regulation by IFN-α2 in Triple-Negative Breast Cancer.
    Brown SR; Vomhof-DeKrey EE; Al-Marsoummi S; Brown ND; Hermanson K; Basson MD
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer.
    Xu J; Chen S; Liang J; Hao T; Wang H; Liu G; Jin X; Li H; Zhang J; Zhang C; He Y
    Front Immunol; 2022; 13():922138. PubMed ID: 36090985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells.
    Puck A; Aigner R; Modak M; Cejka P; Blaas D; Stöckl J
    Results Immunol; 2015; 5():23-32. PubMed ID: 26623250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of bulk and single-cell RNA sequencing data reveals Schlafen-5 (SLFN5) as a novel prognosis and immunity.
    Wu YJ; Chiao CC; Chuang PK; Hsieh CB; Ko CY; Ko CC; Chang CF; Chen TY; Nguyen NUN; Hsu CC; Chu TH; Fang CC; Tsai HY; Tsai HC; Anuraga G; Ta HDK; Xuan DTM; Kumar S; Dey S; Wulandari FS; Manalu RT; Ly NP; Wang CY; Lee YK
    Int J Med Sci; 2024; 21(12):2348-2364. PubMed ID: 39310264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells.
    Katsoulidis E; Mavrommatis E; Woodard J; Shields MA; Sassano A; Carayol N; Sawicki KT; Munshi HG; Platanias LC
    J Biol Chem; 2010 Dec; 285(51):40333-41. PubMed ID: 20956525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
    Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
    Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy.
    Raafat Elsayed AA; Al-Marsoummi S; Vomhof-Dekrey EE; Basson MD
    Cancer Genomics Proteomics; 2022; 19(3):328-338. PubMed ID: 35430566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schlafen 12 Slows TNBC Tumor Growth, Induces Luminal Markers, and Predicts Favorable Survival.
    Singhal SK; Al-Marsoummi S; Vomhof-DeKrey EE; Lauckner B; Beyer T; Basson MD
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schlafen 12 Is Prognostically Favorable and Reduces C-Myc and Proliferation in Lung Adenocarcinoma but Not in Lung Squamous Cell Carcinoma.
    Al-Marsoummi S; Pacella J; Dockter K; Soderberg M; Singhal SK; Vomhof-DeKrey EE; Basson MD
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schlafen 12 mediates the effects of butyrate and repetitive mechanical deformation on intestinal epithelial differentiation in human Caco-2 intestinal epithelial cells.
    Chaturvedi LS; Wang Q; More SK; Vomhof-DeKrey EE; Basson MD
    Hum Cell; 2019 Jul; 32(3):240-250. PubMed ID: 30875077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schlafen 12 Interaction with SerpinB12 and Deubiquitylases Drives Human Enterocyte Differentiation.
    Basson MD; Wang Q; Chaturvedi LS; More S; Vomhof-DeKrey EE; Al-Marsoummi S; Sun K; Kuhn LA; Kovalenko P; Kiupel M
    Cell Physiol Biochem; 2018; 48(3):1274-1290. PubMed ID: 30045019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone H4K12 lactylation promotes malignancy progression in triple-negative breast cancer through SLFN5 downregulation.
    Li J; Chen Z; Jin M; Gu X; Wang Y; Huang G; Zhao W; Lu C
    Cell Signal; 2024 Dec; 124():111468. PubMed ID: 39395526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural, molecular, and functional insights into Schlafen proteins.
    Jo U; Pommier Y
    Exp Mol Med; 2022 Jun; 54(6):730-738. PubMed ID: 35768579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schlafen 12 expression modulates prostate cancer cell differentiation.
    Kovalenko PL; Basson MD
    J Surg Res; 2014 Jul; 190(1):177-84. PubMed ID: 24768141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and regulatory effects of murine Schlafen (Slfn) genes in malignant melanoma and renal cell carcinoma.
    Mavrommatis E; Arslan AD; Sassano A; Hua Y; Kroczynska B; Platanias LC
    J Biol Chem; 2013 Nov; 288(46):33006-15. PubMed ID: 24089532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vil-Cre specific Slfn3KO mice exhibit sex-specific differences in lung, stomach, cecum, kidney, and proximal colon differentiation markers and Slfn family members expression levels.
    Vomhof-DeKrey EE; Rajpathy OK; Preszler E; Basson MD
    Biochem Biophys Rep; 2023 Dec; 36():101552. PubMed ID: 38076659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
    Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.
    Jovanović B; Beeler JS; Pickup MW; Chytil A; Gorska AE; Ashby WJ; Lehmann BD; Zijlstra A; Pietenpol JA; Moses HL
    Breast Cancer Res; 2014 Jul; 16(4):R69. PubMed ID: 24985072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.